KCT0008994尚未招募Unknown
A Prospective Investigator-initiated Study for dose-finding of lenalidomide in Multiple Myeloma (MM) Patients with Impaired Renal Function
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 19(Year) 至 72(Year)（—）
- 性别
- All
入选标准
- •Eligibility Criteria (All of the following must be met):
- •1)Male or female aged 19 to less than 72 years
- •2)Patients with multiple myeloma according to the IMWG criteria (see 19. Other Necessary Matters for Safe and Scientific Clinical Research for reference)
- •3)Patients diagnosed with multiple myeloma meeting the following criteria (all of the following must be met):
- •Monoclonal plasma cells in the bone marrow
- •=10% or confirmed plasmacytoma by tissue examination
- •Patients with evaluable multiple myeloma and one or more of the following:
- •i. Serum M-protein = 0.5 g/dL or urine M-protein = 200 mg/24 hours
- •ii. IgA multiple myeloma: Serum M-protein = 0.5 g/dL or urine M-protein = 200 mg/24 hours
- •iii. Light chain multiple myeloma: Serum free light chain (sFLC) = 100 mg/L and abnormal serum kappa/lambda free light chain ratio
- •4)Patients who are intended to receive lenalidomide maintenance therapy* as the first-line treatment following autologous hematopoietic stem cell transplantation and who have not received lenalidomide treatment previously
- •*Lenalidomide maintenance therapy is defined as the use for long-term disease control purposes without evidence of disease progression of multiple myeloma within 180 days from the autologous hematopoietic stem cell transplantation
- •The criterion for the autologous hematopoietic stem cell transplantation is defined as the first autologous stem cell transplantation if it is terminated once, and as the second autologous stem cell transplantation if it is performed twice consecutively (Tandem autologous stem cell transplantation)
- •This selection criterion is identical to the criteria for health insurance application in the current medical field in Korea
- •5)Renal dysfunction: eGFR < 60 mL/min
- •6)Patients with appropriate liver function (both of the following must be met)
- •Serum total bilirubin less than twice the upper limit of normal (however, less than three times the upper limit of normal in cases of Gilbert's syndrome)
- •AST/ALT less than 2.5 times the upper limit of normal
- •7)Overall performance status (Eastern Cooperative Oncology Group Performance Status) 0-2
- •8)Normal cardiac function (Ejection fraction = 45%)
- •9)Appropriate marrow function (all of the following must be met)
- •Neutrophil count = 1,000/µL
- •Platelet count = 70,000/µL
- •Hemoglobin = 9 g/dL
- •10)For female subjects,
- •Period of amenorrhea for 1 year or more (postmenopausal women), or
- •Negative pregnancy test before the start of treatment (screening) and able to maintain contraception during the study participation period for women [applies to premenopausal women or women with a period of amenorrhea of less than 1 year (within 1 year after menopause)]
- •*During the consent process for fertile women, the subject is informed about natural cycle methods, abstinence, and other contraceptive methods according to the Catholic ideology of the institution.
排除标准
- •Exclusion criteria are as follows
- •1)Asymptomatic multiple myeloma (smoldering multiple myeloma), active plasma cell leukemia, monoclonal gammopathy of undetermined significance (MGUS), amyloidosis, or multiple myeloma involving the central nervous system
- •2)Active cardiovascular dysfunction
- •3)HIV positive
- •4)Active hepatitis A, B, or C
- •5)Patients with cancers other than multiple myeloma currently undergoing or in need of treatment
- •6)Patients with a history of other cancers, excluding cured non-melanoma skin cancer and in situ carcinoma of the cervix within the past 5 years
- •7)Peripheral neuropathy of grade 3 or higher or peripheral neuropathy with pain of grade 2 or higher
- •8)Participation in another clinical study involving the administration of anti-neoplastic agents within the last 3 weeks
- •9)Platelet or red blood cell transfusion within 14 days of Cycle 1 Day 1
- •10)Administration of hematopoietic growth factors such as G-CSF, GM-CSF, erythropoietin, or megakaryocyte growth factor within 14 days of Cycle 1 Day 1
- •11)Concurrent severe psychiatric illness making the patient unable to participate in the study
- •12)Pregnant women
研究者
相似试验
尚未招募
Unknown
A Prospective Investigator-initiated Study to explore the optimal dose of lenalidomide in combination therapy for patients with Multiple Myeloma Featuring Renal DysfunctioKCT0009561The Catholic University of Korea, Seoul St. Mary's Hospital30
招募中
不适用
on-interventional prospective research study by d-uo on intravesical instillation of mitomycin C in non-muscle invasive bladder cancerC67Malignant neoplasm of bladderDRKS00017069d-uo Deutsche Uro-Onkologen (Interessenverband zur Qualitätssicherung in der Uro-Onkologie in Deutschland e.V.)500
已完成
不适用
Prospective Exploratory Study to Investigate the Efficacy of Amino Acid Jelly in Cancer PatientsTerminal phase of CancerJPRN-UMIN000006936Interfaculty Initiative in Information Studies, The University of Tokyo Department of Palliative Medicine, The University of Tokyo Hospital27
招募中
不适用
Prospective study with the aim to investigate the biological relevance of fibrinolysis products and their use as prognostic and therapeutic biomarkers in SIRS and SEPSIS.A41.9Sepsis, unspecifiedDRKS00000215Klinik für Anästhesiologie, Intensivmedizin und SchmerztherapieKlinikum der J.W.-Goethe Universität150
进行中（未招募）
2 期
The safety and efficacy of ALARM-TD-V1 for sleep-disordered breathingSleep-disordered breathingD020181Obstructive Sleep Apnea SyndromeJPRN-jRCT2052230034Sato Susumu40